Manufacturer
DUOPHARMA (M) SDN. BHD.
Contents
Diclofenac Na
Indication
Renal colic,Acute gout, Acute pain, Osteoarthritis, Pain after accidental trauma, Postoperative pain, Rheumatoid arthritis,Acute pain,Postoperative pain,
Instruction
Administer via IM injection/IV infusion.
Drug interaction
Increased risk of gastrointestinal ulceration, perforation or haemorrhage with other corticosteroids, SSRIs. Increased risk CV-related adverse reactions with cardiac glycosides. Increased risk of hyperkalaemia and renal toxicity with ACE inhibitors, diuretics, ciclosporin, tacrolimus. Increased risk of haematological toxicity with zidovudine. Increased levels and risk of toxicity with digoxin, lithium, methotrexate, pemetrexed, phenytoin. Decreased effect with colestipol, cholestyramine. Decrease effect of mifepristone. Increased peak plasma concentration with CYP2C9 inhibitors e.g. voriconazole. Potentially Fatal: Increased risk of gastrointestinal ulceration, perforation or haemorrhage with other NSAIDs (e.g. aspirin), antiplatelets, anticoagulants (e.g. warfarin).
Malaysia
